{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:41:35Z","timestamp":1784256095836,"version":"3.55.0"},"reference-count":47,"publisher":"Institute of Physiology of the Czech Academy of Sciences","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"published-print":{"date-parts":[[2019,11,30]]},"abstract":"<jats:p>This article is focused on endocrine-mediated osteoporosis caused by growth hormone (GH) disorders; adult GH deficiency and acromegaly. GH and insulin like growth factor-1 (IGF-1) stimulate linear bone growth through complex hormonal interactions and activates epiphyseal prechondrocytes. GH, via receptor activator of nuclear factor-kappaB (RANK), its ligand (RANK-L), and the osteoprotegerin system, stimulates production of osteoprotegerin and its accumulation in bone matrix. Malfunction of this mechanism, could lead to specific bone impairment. However, the primary problem of bone disease in GH secretion disorders is the primary prevention of osteoporotic fractures, so it is important to determine bone quality that better reflects the patient's actual predisposition to fracture. A method estimating bone quality from lumbar spine dual X-ray absorptiometry (DXA) scans is trabecular bone score (TBS). TBS in addition to bone mineral density (BMD) is a promising predictor of the osteoporotic fracture risk in women with postmenopausal osteopenia. In acromegaly TBS better defines risk of fracture because BMD is normal or even increased. TBS helps to monitor the effect of growth hormone therapy. Despite these findings, TBS shouldn\u00b4t be used alone, but a comprehensive consideration of all fracture risk factors, BMD and bone turnover markers is necessary.<\/jats:p>","DOI":"10.33549\/physiolres.934303","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T09:31:01Z","timestamp":1576488661000},"page":"S121-S129","source":"Crossref","is-referenced-by-count":18,"title":["Pathophysiology of Growth Hormone Secretion Disorders and Their Impact on Bone Microstructure as Measured by Trabecular Bone Score"],"prefix":"10.33549","author":[{"given":"M.","family":"KU\u017dMA","sequence":"first","affiliation":[{"name":"5th Department of Internal Medicine, Faculty of Medicine, Comenius University Bratislava, University Hospital Bratislava, Bratislava, Slovak Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"KILLINGER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"JACKULIAK","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"VA\u0147UGA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"HANS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"BINKLEY","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"PAYER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"19169","published-online":{"date-parts":[[2019,11,30]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"AMATO G, CARELLA C, FAZIO S, LA MG, CITTADINI A, SABATINI D, MARCIANO-MONE C, SACCA L, BELLASTELLA A: Body composition, bone metabolism, and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 77: 1671-1676, 1993.","DOI":"10.1210\/jcem.77.6.8263158"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"AMERI P, GIUSTI A, BOSCHETTI M, BOVIO M, TETI C, LEONCINI G, FERONE D, MURIALDO G, MINUTO F: Vitamin D increases circulating IGF1 in adults: potential implication for the treatment of GH deficiency. Eur J Endocrinol 169: 767-772, 2013.","DOI":"10.1530\/eje-13-0510"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"APPELMAN-DIJKSTRA NM, CLAESSEN KM, HAMDY NA, PEREIRA AM, BIERMASZ NR: Effects of up to 15 years of recombinant human GH (rhGH) replacement on bone metabolism in adults with growth hormone deficiency (GHD): the Leiden Cohort Study. Clin Endocrinol (Oxf) 81: 727-735, 2014.","DOI":"10.1111\/cen.12493"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"ARWERT LI, DEIJEN JB, MULLER M, DRENT ML: Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm Behav 47: 343-349, 2005.","DOI":"10.1016\/j.yhbeh.2004.11.015"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"BARAKE M, KLIBANSKI A, TRITOS NA: Effects of recombinant human growth hormone therapy on bone mineral density in adults with growth hormone deficiency: a meta-analysis. J Clin Endocrinol Metab 99: 852-860, 2014.","DOI":"10.1210\/jc.2013-3921"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"BEREKET A, CESUR Y, OZKAN B, ADAL E, TURAN S, ONAN SH, DONERAY H, AKCAY T, HAKLAR G: Circulating insulin-like growth factor binding protein-4 (IGFBP-4) is not regulated by parathyroid hormone and vitamin D in vivo: evidence from children with rickets. J Clin Res Pediatr Endocrinol 2: 17-20, 2010.","DOI":"10.4274\/jcrpe.v2i1.17"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"BIERMASZ NR, HAMDY NA, JANSSEN YJ, ROELFSEMA F: Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial. J Clin Endocrinol Metab 86: 3079-3085, 2001.","DOI":"10.1210\/jcem.86.7.7669"},{"key":"ref7","unstructured":"BOGAZZI F, ROSSI G, LOMBARDI M, TOMISTI L, SARDELLA C, MANETTI L, CURZIO O, MARCOCCI C, GRASSO L, GASPERI M, MARTINO E: Vitamin D status may contribute to serum insulin-like growth factor I concentrations in healthy subjects. J Endocrinol Invest 34: e200-203, 2011."},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"BONADONNA S, MAZZIOTTI G, NUZZO M, BIANCHI A, FUSCO A, DE MARINIS L, GIUSTINA A: Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20: 1837-1844, 2005.","DOI":"10.1359\/jbmr.050603"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"BOUTROY S, HANS D, SORNAY-RENDU E, VILAYPHIOU N, WINZENRIETH R, CHAPURLAT R: Trabecular bone score improves fracture risk prediction in non-osteoporotic women: the OFELY study. Osteoporos Int 24: 77-85, 2013.","DOI":"10.1007\/s00198-012-2188-2"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"BRIOT K, PATERNOTTE S, KOLTA S, EASTELL R, REID DM, FELSENBERG D, GLUER CC, ROUX C: Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: the OPUS study. Bone 57: 232-236, 2013.","DOI":"10.1016\/j.bone.2013.07.040"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"CARBONARE LD, MICHELETTI V, COSARO E, VALENTI MT, MOTTES M, FRANCIA G, DAVI MV: Bone histomorphometry in acromegaly patients with fragility vertebral fractures. Pituitary 21: 56-64, 2018.","DOI":"10.1007\/s11102-017-0847-1"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"CLAESSEN KM, KROON HM, PEREIRA AM, APPELMAN-DIJKSTRA NM, VERSTEGEN MJ, KLOPPENBURG M, HAMDY NA, BIERMASZ NR: Progression of vertebral fractures despite long-term biochemical control of acromegaly: a prospective follow-up study. J Clin Endocrinol Metab 98: 4808-4815, 2013.","DOI":"10.1210\/jc.2013-2695"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"CLANGET C, SECK T, HINKE V, WUSTER C, ZIEGLER R, PFEILSCHIFTER J: Effects of 6 years of growth hormone (GH) treatment on bone mineral density in GH-deficient adults. Clin Endocrinol (Oxf) 55: 93-99, 2001.","DOI":"10.1046\/j.1365-2265.2001.01284.x"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"CONWAY GS, SZARRAS-CZAPNIK M, RACZ K, KELLER A, CHANSON P, TAUBER M, ZACHARIN M: Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol 160: 899-907, 2009.","DOI":"10.1530\/eje-08-0436"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"DAVIDSON P, MILNE R, CHASE D, COOPER C: Growth hormone replacement in adults and bone mineral density: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 60: 92-98, 2004.","DOI":"10.1111\/j.1365-2265.2004.01935.x"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"DEGERBLAD M, BENGTSSON BA, BRAMNERT M, JOHNELL O, MANHEM P, ROSEN T, THOREN M: Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 133: 180-188, 1995.","DOI":"10.1530\/eje.0.1330180"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"ELBORNSSON M, GOTHERSTROM G, BOSAEUS I, BENGTSSON BA, JOHANNSSON G, SVENSSON J: Fifteen years of GH replacement increases bone mineral density in hypopituitary patients with adult-onset GH deficiency. Eur J Endocrinol 166: 787-795, 2012a.","DOI":"10.1530\/eje-11-1072"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"ELBORNSSON M, GOTHERSTROM G, FRANCO C, BENGTSSON BA, JOHANNSSON G, SVENSSON J: Effects of 3-year GH replacement therapy on bone mineral density in younger and elderly adults with adult-onset GH deficiency. Eur J Endocrinol 166: 181-189, 2012b.","DOI":"10.1530\/eje-11-0886"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"GODANG K, OLARESCU NC, BOLLERSLEV J, HECK A: Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study. Eur J Endocrinol 175: 155-164, 2016.","DOI":"10.1530\/endoabs.41.gp150"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"GOMEZ JM, MARAVALL FJ, GOMEZ N, NAVARRO MA, CASAMITJANA R, SOLER J: Relationship between 25-(OH) D3, the IGF-I system, leptin, anthropometric and body composition variables in a healthy, randomly selected population. Horm Metab Res 36: 48-53, 2004.","DOI":"10.1055\/s-2004-814103"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"HALUPCZOK-ZYLA J, JAWIARCZYK-PRZYBYLOWSKA A, BOLANOWSKI M: Patients with active acromegaly are at high risk of 25(OH)D deficiency. Front Endocrinol (Lausanne) 6: 89, 2015.","DOI":"10.3389\/fendo.2015.00089"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"HANS D, GOERTZEN AL, KRIEG MA, LESLIE WD: Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res 26: 2762-2769, 2011.","DOI":"10.1002\/jbmr.499"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"HONG AR, KIM JH, KIM SW, KIM SY, SHIN CS: Trabecular bone score as a skeletal fragility index in acromegaly patients. Osteoporos Int 27: 1123-1129, 2016.","DOI":"10.1007\/s00198-015-3344-2"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"JORGENSEN AP, FOUGNER KJ, UELAND T, GUDMUNDSEN O, BURMAN P, SCHREINER T, BOLLERSLEV J: Favorable long-term effects of growth hormone replacement therapy on quality of life, bone metabolism, body composition and lipid levels in patients with adult-onset growth hormone deficiency. Growth Horm IGF Res 21: 69-75, 2011.","DOI":"10.1016\/j.ghir.2011.01.001"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"JOSEPH F, AHMAD AM, UL-HAQ M, DURHAM BH, WHITTINGHAM P, FRASER WD, VORA JP: Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis. J Bone Miner Res 23: 721-729, 2008.","DOI":"10.1359\/jbmr.071117"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"KAYATH MJ, VIEIRA JG: Osteopenia occurs in a minority of patients with acromegaly and is predominant in the spine. Osteoporos Int 7: 226-230, 1997.","DOI":"10.1007\/bf01622293"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"KRANTZ E, TRIMPOU P, LANDIN-WILHELMSEN K: Effect of growth hormone treatment on fractures and quality of life in postmenopausal osteoporosis: A 10-year follow-up study. J Clin Endocrinol Metab 100: 3251-3259, 2015.","DOI":"10.1210\/jc.2015-1757"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"KUZMA M, BINKLEY N, BEDNAROVA A, KILLINGER Z, VANUGA P, PAYER J: Trabecular bone score change differs with regard to 25(oh)d levels in patients treated for adult-onset growth hormone deficiency. Endocr Pract 22: 951-958, 2016.","DOI":"10.4158\/ep151183.or"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"KUZMA M, KUZMOVA Z, ZELINKOVA Z, KILLINGER Z, VANUGA P, LAZUROVA I, TOMKOVA S, PAYER J: Impact of the growth hormone replacement on bone status in growth hormone deficient adults. Growth Horm IGF Res 24: 22-28, 2014.","DOI":"10.1016\/j.ghir.2013.12.001"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"KUZMA M, VANUGA P, SAGOVA I, PAVAI D, JACKULIAK P, KILLINGER Z, BINKLEY NC, WINZENRIETH R, GENANT HK, PAYER J: Non-invasive DXA-derived bone structure assessment of acromegaly patients: a cross-sectional study. Eur J Endocrinol 180: 201-211, 2019.","DOI":"10.1530\/eje-18-0881"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"MAFFEZZONI F, MADDALO M, FRARA S, MEZZONE M, ZORZA I, BARUFFALDI F, DOGLIETTO F, MAZZIOTTI G, MAROLDI R, GIUSTINA A: High-resolution-cone beam tomography analysis of bone microarchitecture in patients with acromegaly and radiological vertebral fractures. Endocrine 54: 532-542, 2016.","DOI":"10.1007\/s12020-016-1078-3"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"MALGO F, HAMDY NAT, PAPAPOULOS SE, APPELMAN-DIJKSTRA NM: Bone material strength index as measured by impact microindentation is low in patients with fractures irrespective of fracture site. Osteoporos Int 28: 2433-2437, 2017.","DOI":"10.1007\/s00198-017-4054-8"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"MAZZIOTTI G, BIAGIOLI E, MAFFEZZONI F, SPINELLO M, SERRA V, MAROLDI R, FLORIANI I, GIUSTINA A: Bone turnover, bone mineral density, and fracture risk in acromegaly: a meta-analysis. J Clin Endocrinol Metab 100: 384-394, 2015.","DOI":"10.1210\/jc.2014-2937"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"MAZZIOTTI G, BIANCHI A, PORCELLI T, MORMANDO M, MAFFEZZONI F, CRISTIANO A, GIAMPIETRO A, DE MARINIS L, GIUSTINA A: Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98: 3402-3410, 2013.","DOI":"10.1210\/jc.2013-1460"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"MCCLOSKEY EV, ODEN A, HARVEY NC, LESLIE WD, HANS D, JOHANSSON H, BARKMANN R, BOUTROY S, BROWN J, CHAPURLAT R, ELDERS PJM, FUJITA Y, GLUER CC, GOLTZMAN D, IKI M, KARLSSON M, KINDMARK A, KOTOWICZ M, KURUMATANI N, KWOK T, LAMY O, LEUNG J, LIPPUNER K, LJUNGGREN O, LORENTZON M, MELLSTROM D, MERLIJN T, OEI L, OHLSSON C, PASCO JA, RIVADENEIRA F, ROSENGREN B, SORNAY-RENDU E, SZULC P, TAMAKI J, KANIS JA: A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res 31: 940-948, 2016.","DOI":"10.1002\/jbmr.2734"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"MIRZA F, CANALIS E: Management of endocrine disease: Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol 173: R131-151, 2015.","DOI":"10.1530\/eje-15-0118"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"MO D, FLESERIU M, QI R, JIA N, CHILD CJ, BOUILLON R, HARDIN DS: Fracture risk in adult patients treated with growth hormone replacement therapy for growth hormone deficiency: a prospective observational cohort study. Lancet Diabetes Endocrinol 3: 331-338, 2015.","DOI":"10.1016\/s2213-8587(15)00098-4"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"RIGGS BL, RANDALL RV, WAHNER HW, JOWSEY J, KELLY PJ, SINGH M: The nature of the metabolic bone disorder in acromegaly. J Clin Endocrinol Metab 34: 911-918, 1972.","DOI":"10.1210\/jcem-34-6-911"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"ROSEN T, WIREN L, WILHELMSEN L, WIKLUND I, BENGTSSON BA: Decreased psychological well-being in adult patients with growth hormone deficiency. Clin Endocrinol (Oxf) 40: 111-116, 1994.","DOI":"10.1111\/j.1365-2265.1994.tb02452.x"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"ROTA F, SAVANELLI MC, TAUCHMANOVA L, SAVASTANO S, LOMBARDI G, COLAO A, DI SC: Bone density and turnover in young adult patients with growth hormone deficiency after 2-year growth hormone replacement according with gender. J Endocrinol Invest 31: 94-102, 2008.","DOI":"10.1007\/bf03345574"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"SCILLITANI A, CHIODINI I, CARNEVALE V, GIANNATEMPO GM, FRUSCIANTE V, VILLELLA M, PILERI M, GUGLIELMI G, DI GIORGIO A, MODONI S, FUSILLI S, DI CERBO A, LIUZZI A: Skeletal involvement in female acromegalic subjects: the effects of growth hormone excess in amenorrheal and menstruating patients. J Bone Miner Res 12: 1729-1736, 1997.","DOI":"10.1359\/jbmr.1997.12.10.1729"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"SOLIMAN AT, AL KHALAF F, ALHEMAIDI N, AL ALI M, AL ZYOUD M, YAKOOT K: Linear growth in relation to the circulating concentrations of insulin-like growth factor I, parathyroid hormone, and 25-hydroxy vitamin D in children with nutritional rickets before and after treatment: endocrine adaptation to vitamin D deficiency. Metabolism 57: 95-102, 2008.","DOI":"10.1016\/j.metabol.2007.08.011"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"STEPAN J, MAREK J, HAVRANEK T, DOLEZAL V, PACOVSKY V: Bone isoenzyme of serum alkaline phosphatase in acromegaly. Clin Chim Acta 93: 355-363, 1979.","DOI":"10.1016\/0009-8981(79)90285-7"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"TOUSKOVA V, KLOUCKOVA J, DUROVCOVA V, LACINOVA Z, KAVALKOVA P, TRACHTA P, KOSAK M, MRAZ M, HALUZIKOVA D, HANA V, MAREK J, KRSEK M, HALUZIK M: The possible role of mRNA expression changes of GH\/IGF-1\/insulin axis components in subcutaneous adipose tissue in metabolic disturbances of patients with acromegaly. Physiol Res 65: 493-503, 2016.","DOI":"10.3109\/07435800.2016.1169544"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"UELAND T, BOLLERSLEV J, GODANG K, MULLER F, FROLAND SS, AUKRUST P: Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis. Eur J Endocrinol 145: 685-690, 2001.","DOI":"10.1530\/eje.0.1450685"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"VESTERGAARD P, MOSEKILDE L: Fracture risk is decreased in acromegaly - a potential beneficial effect of growth hormone. Osteoporos Int 15: 155-159, 2004.","DOI":"10.1007\/s00198-003-1531-z"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T09:31:07Z","timestamp":1576488667000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2019\/68_S121.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,30]]},"references-count":47,"URL":"https:\/\/doi.org\/10.33549\/physiolres.934303","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,30]]}}}